Ketamine & Psychedelic Therapy in Europe for International Patients: Where Cross-Border Treatment Actually Works (2026)

The direct answer first. If there is no suitable licensed option where you live, travelling for treatment inside Europe is realistic in a specific, limited way: private, self-paid ketamine or esketamine treatment for a visiting patient is legal and practised in Czechia, Germany, the UK, Austria and Spain (Portugal likely, less documented), impractical in the Netherlands (referral-gated system, no private channel), and (for psychedelic-assisted therapy with psilocybin, LSD or MDMA) closed in Switzerland to anyone not resident there, which matters because Switzerland is the only European country where that therapy is legal outside research at all. What follows is the country-by-country reality, the visa mechanics, verified prices, and the honest limits of each route.

This guide is for two situations that end in the same place: you live in a European country where the directory shows no suitable verified option (Ireland, France, Italy, much of Central and Eastern Europe), or you live outside Europe and are considering treatment here. Either way, the questions are identical: who will legally treat a non-resident, what does entry for treatment look like, what does it cost, and where do the honest limits lie. For the substance-by-substance legal map, start with where in Europe you can actually get psychedelic therapy; this page adds the cross-border layer.

One framing note: this is not "medical tourism" in the brochure sense. Nobody should board a plane for a discount. The realistic reasons to travel are access (your country has no licensed route at all) and language (you need therapy in a language you actually speak; see our verified list of English-speaking providers). Psychotherapy-based treatment also argues for continuity: the best cross-border plan includes who follows you up at home, agreed before you travel.

The three rules that decide everything

Rule 1: private self-pay treatment of a foreign patient is not banned anywhere we checked. Across Germany, Switzerland, the Netherlands, Austria, the UK, Czechia, Portugal and Spain, we found no statute that conditions private medical treatment on residency or citizenship. Restrictions live elsewhere: in what public insurance will pay for (which never covers visitors), in referral gates built for the domestic system, and in individual clinics' own intake policies.

Rule 2: the exception is Switzerland, and it is the exception that matters most. Switzerland is the only European country where psychedelic-assisted therapy with LSD, MDMA or psilocybin is legal outside clinical trials, through federal exceptional-use authorisations (Art. 8 Abs. 5 BetmG). The Federal Office of Public Health states the condition directly: authorisations are issued only to physicians licensed to practise in Switzerland "für die Behandlung von Patientinnen und Patienten mit Schweizer Wohnsitz", for the treatment of patients resident in Switzerland. There is no legal Swiss PAT route for a visiting patient. (Ketamine and esketamine in Switzerland sit outside this authorisation regime and follow the ordinary self-pay logic: several private clinics offer them.)

Rule 3: what's legal and what's practical are different questions. The law may be open while the system is closed (the Netherlands: no prohibition, but treatment runs through insurer-contracted mental-health care behind a referral, and no private self-pay ketamine channel exists), or the system may be open while individual clinics simply haven't decided their policy on visiting patients. Very few clinics publish an international-patients policy. Treat every "yes" below as "yes, and confirm your situation when you enquire".

Country by country: where a visiting patient stands

Czechia: the most formalised door

Psyon in Prague is the clearest case in Europe of a clinic that has built an actual track for foreign self-payers: the entire ketamine-assisted therapy process is available in English, its price list carries a dedicated "Self-payers — customers of other insurance companies" category, and payments are accepted in euros at a published exchange rate. The process is self-contained: an online interview, a full psychiatric assessment by their own physician, somatic screening (bloods, ECG), then a minimum course of five sessions, so no external referral is needed. Spravato in Czechia, by contrast, is not a visitor's route: public reimbursement runs through inducing centres gated by a Czech outpatient psychiatrist's referral and a six-month treatment frame.

Germany: the strongest infrastructure for treatment travel

Ketamine for depression in Germany is a prescription-medicine (AMG) matter, not a narcotics-law one, and off-label prescribing is explicitly permitted: the constraints are documentation and consent, not patient origin. Practically, private clinics run courses of 4–6 infusions over 2–3 weeks (Ketaneo in Mannheim: no referral required, first consultation plus ECG and recent labs, €230–250 per infusion), which fits comfortably inside a 90-day Schengen stay. OVID Clinics Berlin, private-insurance and self-pay only, publishes outpatient KAP at €6,500–7,500, a four-week day-clinic programme around €12,000, and a psilocybin compassionate-use programme (the only one of its kind in the EU, under BfArM §3 BtMG since July 2025) around €20,000 for a minimum six weeks, with the team working in German, English, Spanish and Turkish. Germany also institutionalises entry for treatment: up to 90 days on a standard Schengen C visa, longer on a residence permit specifically for medical treatment as a self-payer.

United Kingdom: the only country with treatment travel written into immigration law

UK immigration rules (Appendix V) explicitly allow visits for private medical treatment: arrange the treatment before travelling, carry a letter from the UK clinician (diagnosis, cost, expected duration), and the visitor route runs up to 11 months with a possible 6-month extension, the only such codified route in Europe. EU citizens need only an ETA. On the treatment side, CQC-registered private ketamine clinics operate openly (Save Minds in London: no GP referral, mandatory psychiatric consultation £450, sessions £595–990, typical programmes 15–20 sessions over 4–6 months, note that length against your stay). Spravato is not available on the NHS in England and Wales (NICE TA854), but has been available privately since September 2020; an NHS trust's self-funded price list puts the drug at £591–754 per dose plus roughly £265 per visit.

Austria: quiet but open

Ketamine sits outside Austria's narcotics law, and off-label intravenous use is legally framed as an ordinary therapeutic trial (§8 öAMG). Private Vienna practices: Zentrum für Augmentierte Therapie, Dr. Buchmayer, Dr. Platz: treat self-payers; the Spravato induction pattern (8 treatments in 4 weeks) is published by private providers, and Austria's foreign ministry maintains a formal medical-treatment visa procedure. Psilocybin therapy outside trials is prohibited.

Spain: open, with a stricter off-label frame

Spain's off-label rule (RD 1015/2009) requires exceptional-use justification (case-by-case, documented, with no authorised alternative), which makes the ketamine-infusion frame legally tighter than in Germany or Czechia, though private clinics in Barcelona, Madrid and Seville practise it. For Spravato the picture is cleaner: the private channel is legally independent of the public system, running through expressly authorised centres, one such centre, Alcalamente in Madrid, states this directly ("por vía privada, solo se puede a través de centros autorizados") and has publicly responded to an enquiry from a patient in Greece with an invitation to a video assessment. A Spravato induction fits a Schengen stay; maintenance does not.

The Netherlands: legal on paper, closed in practice

No Dutch rule bans treating a foreign self-payer. But (es)ketamine for depression is concentrated in academic and insurer-contracted mental-health institutions behind a mandatory referral, Dutch professional guidance requires a valid referral even when a patient offers to pay privately, and we could not find a single private self-pay ketamine clinic serving visitors. Spravato adds a fourth-line reimbursement gate and insurer pre-authorisation. Treat the Netherlands as effectively unavailable for treatment travel. (The famous Dutch truffle retreats are not licensed medicine and sit outside this directory's scope.)

Switzerland: two different answers

For psychedelic-assisted therapy: closed to non-residents, as above, and worth restating, because search engines and AI assistants routinely recommend "Switzerland" to foreigners looking for legal psilocybin therapy. For ketamine and esketamine: the ordinary private logic applies, several clinics (Privatklinik Meiringen, KetaminTherapieZentrum Luzern and others) treat self-payers, and no residency rule was found, though none of the psychiatric ketamine providers we checked publishes an international-patients policy, so enquire first. Many Swiss practitioners publish their consultation languages: the Switzerland directory page can be filtered by language.

Portugal: likely open, thinnest evidence

Off-label responsibility sits with the physician, private ketamine practice exists (Liminal Minds in Lisbon operates fully in English with online consultations), and nothing we found requires residency. But no provider publishes an international-patients policy or prices, so this is the least documented of the open countries: enquire and confirm everything.

The Spravato arithmetic every visitor needs

Esketamine (Spravato) is the one EU-approved psychedelic-adjacent treatment, so it travels best on paper, but its schedule is the constraint. Induction means roughly 8 supervised visits in 4 weeks, each with a two-hour observation window; that fits a 90-day Schengen stay or a UK visit with margin. The problem is what follows: maintenance typically runs six months or longer at one visit every one to two weeks. For a visitor that leaves three honest options: a long-stay route (the UK's 11-month private-treatment visa is the clean solution), relocating temporarily, or agreeing before you start how care transfers to a clinician at home, which requires esketamine to be available at home, which is usually the reason you travelled in the first place. Do this arithmetic before paying for an induction. Self-pay drug costs alone run roughly €600 per 84 mg session in Germany and £591–754 per dose in the UK; see the cost index for the full picture.

What about EU cross-border healthcare rights?

EU citizens have a right to seek healthcare in other member states (Directive 2011/24/EU), and it covers private providers. In practice it rarely pays for anything here: your home system reimburses only treatments in its own benefit basket, at its own rates, often with prior authorisation, and off-label ketamine or KAP is in almost nobody's basket. Where Spravato is reimbursed at home, a claim for treatment abroad is theoretically arguable and practically fragile (centre requirements, therapy-line criteria, authorisation rules). Plan every route on this page as self-pay, and treat any reimbursement as a bonus your insurer has confirmed in writing beforehand. Non-EU citizens are outside the mechanism entirely; so is the UK.

Why trials are not a travel route

Clinical trials are often the only legal door to psilocybin, MDMA and other classic psychedelics, and they are open in more countries than any approved treatment. But cross-border participation is rare for structural reasons: therapy and consent run in the local language, visit schedules span months with little flexibility, medication wash-outs need supervision by the local team, and UK academic trials generally require being ordinarily resident. By all means check the recruiting-trials index (some sites do consider candidates who can relocate for the duration), but do not build a travel plan on it.

Before you contact any clinic

Ask five things in your first message: whether they accept non-resident self-pay patients (and any conditions); the full course cost in writing, including assessment and observation time; what medical records they need in advance and in which language; what the realistic total schedule is, induction and maintenance; and how they handle follow-up after you leave, who adjusts medication, who responds if things worsen. A clinic that answers all five clearly is telling you something about its quality; the choosing-a-clinic guide covers the rest. Our eligibility check can help you organise the clinical side of that first message: it compares your answers with published access criteria and is not a diagnosis; the formal eligibility decision always happens with the treating clinician.

The honest limits of this page

Three caveats we owe you. First, clinic willingness is the weakest link: outside Psyon's explicit self-payer track, almost no provider publishes an international-patients policy, so every route above ends with "confirm when you enquire". Second, administrative practice can be stricter than statute: Switzerland's residency rule exists only at the level of the authorising office's stated practice, and equivalents elsewhere may exist that we have not found. Third, aftercare is the clinical Achilles' heel of any treatment travel: UK professional guidance is blunt that prescribing for patients who then leave the country demands planned monitoring and continuity, arrange your home follow-up before the first session, not after the last one.

Frequently asked questions

I can't get ketamine therapy in my country. Where in Europe can I actually go?

The realistic self-pay destinations are Czechia (Psyon in Prague runs the process in English with EUR pricing), Germany (2–3-week infusion courses; Berlin and Mannheim clinics documented), the UK (CQC-registered clinics plus a dedicated visitor route for private treatment), Austria and Spain. The Netherlands is effectively closed by process, and Swiss psychedelic-assisted therapy is limited to Swiss residents, though Swiss ketamine clinics follow the ordinary self-pay logic.

Can I travel to Switzerland for legal psilocybin or MDMA therapy?

No. The Swiss federal health office issues the required exceptional-use authorisations only for the treatment of patients resident in Switzerland. Switzerland is the only European country with legal psychedelic-assisted therapy outside research, and that route does not extend to visitors. The legal doors to psilocybin elsewhere are Germany's two-site compassionate-use programme (single justified cases) and clinical trials.

Does travelling for a Spravato induction make sense?

Sometimes, if you solve maintenance first. The induction itself (about 8 supervised visits in 4 weeks) fits a Schengen or UK stay. But guidelines-based treatment continues for six months or more, so you need one of: a long-stay option (the UK's private-medical-treatment visa runs to 11 months), a temporary move, or a clinician at home who can legally continue esketamine, which is rare if your country doesn't offer it. Never start an induction without a written maintenance plan.

Will my insurance or the EU cross-border directive pay for treatment abroad?

Almost certainly not for ketamine or KAP: home systems reimburse only what is in their own benefit basket, and off-label ketamine is in almost none. For Spravato, a reimbursement claim under Directive 2011/24/EU is theoretically possible where it is covered at home, but centre-authorisation and therapy-line rules make it fragile: get written confirmation from your insurer before travelling, and budget as a self-payer.

Do clinics abroad speak my language?

Increasingly documented: our English-speaking providers list covers every provider whose own website confirms English consultation, and provider pages show verified languages from Spanish and Turkish to Polish, with sources. On the Germany and Switzerland country pages you can filter providers by language. Absence of a language badge does not mean the language is not spoken; most providers simply do not publish this.

Sources

• BAG/FOPH: Beschränkte medizinische Anwendung von verbotenen Betäubungsmitteln (residency condition, verbatim): bag.admin.ch
• UK Immigration Rules Appendix V: visitor route for private medical treatment (V 7.1–7.3, V 17.2): gov.uk
• Psyon Prague: English-language ketamine-assisted therapy, self-payer category, EUR pricing: psyon.cz
• OVID Clinics Berlin: cost overview (KAP €6.5–7.5k; day clinic ~€12k; psilocybin compassionate use ~€20k) and working languages: ovid-clinics.com
• Ketaneo Mannheim: FAQ: referral not mandatory, course of 4–6 infusions in 2–3 weeks, €230–250 per infusion: ketaneo.de
• G-BA: permissibility of off-label prescribing in Germany: g-ba.de
• NICE TA854: esketamine not recommended for NHS use in England: nice.org.uk; Oxford Health NHS FT self-funded price FAQ: oxfordhealth.nhs.uk
• Save Minds London: programme structure and prices; CQC registration: saveminds.co.uk, cqc.org.uk
• LVVP (NL): referral required even for self-paying patients in GGZ: lvvp.info; CZ groep esketamine centre criteria: zorginkoopbeleid.cz.nl
• Dr. Buchmayer Vienna: private esketamine programme (8 treatments/4 weeks): dr.buchmayer.eu; BMEIA medical-treatment visa Merkblatt: bmeia.gv.at
• RD 1015/2009 (ES), off-label as exceptional use: boe.es; Alcalamente Madrid, private channel via authorised centres: alcalamente.es
• Directive 2011/24/EU on cross-border healthcare: eur-lex.europa.eu
• GMC: prescribing for patients going overseas (continuity/monitoring): gmc-uk.org
• Cancer Research UK: trials and "ordinarily resident" requirement: cancerresearchuk.org